Stocks and Investing
Stocks and Investing
Fri, August 5, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, August 4, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (BMRN) at Buy with Increased Target to $117 on, Aug 4th, 2022
Matthew Harrison of Morgan Stanley, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $113 to $117 on, Aug 4th, 2022.
Matthew has made no other calls on BMRN in the last 4 months.
There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Andreas Argyrides of "Wedbush" Initiated at Hold and Held Target at $70 on, Monday, June 13th, 2022
These are the ratings of the 2 analyists that currently disagree with Matthew
- Olivia Brayer of "Cantor Fitzgerald" Initiated at Buy and Held Target at $110 on, Wednesday, July 13th, 2022
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $106 on, Monday, June 6th, 2022
Contributing Sources